Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma

Clinical Cancer Research

Volumn 19, Issue 22, 2013, Pages 6173-6182

  Rader, Julieann ^a   Russell, Mike R ^a   Hart, Lori S ^a   Nakazawa, Michael S ^a   Belcastro, Lili T ^a   Martinez, Daniel ^a   Li, Yimei ^a   Carpenter, Erica L ^a   Attiyeh, Edward F ^a   Diskin, Sharon J ^a   Kim, Sunkyu ^c   Parasuraman, Sudha ^c   Caponigro, Giordano ^c   Schnepp, Robert W ^a   Wood, Andrew C ^a   Pawel, Bruce ^a   Cole, Kristina A ^a   Maris, John M ^a,b,d  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^d CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLIN DEPENDENT KINASE INHIBITOR; LEE 011; RETINOBLASTOMA PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CELL AGING; CELL CYCLE ARREST; CELL VIABILITY; CHILD; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOSTASIS; ENZYME INHIBITION; GENE; GENE AMPLIFICATION; GROWTH REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; MOUSE; MYCN GENE; NEUROBLASTOMA; NEUROBLASTOMA CELL; NONHUMAN; PRIORITY JOURNAL; SENESCENCE;

AMINOPYRIDINES; ANIMALS; APOPTOSIS; CELL AGING; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; CHILD; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE 6; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; MICE; MICE, SCID; NEOPLASM TRANSPLANTATION; NEUROBLASTOMA; NUCLEAR PROTEINS; ONCOGENE PROTEINS; PHOSPHORYLATION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN KINASE INHIBITORS; PURINES; RETINOBLASTOMA PROTEIN; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 84888082787     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-1675     Document Type: Article

References (37)

1. Cole KA, Maris JM. New strategies in refractory and recurrent neuroblastoma: translational opportunities to impact patient outcome. Clin Cancer Res 2012;18:2423-8.
2. Maris JM. Recent advances in neuroblastoma. N Engl J Med 2010;362:2202-11.
3. Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet 2007;369:2106-20. (Pubitemid 46935947)
4. Carpenter EL, Mosse YP. Targeting ALK in neuroblastoma-preclinical and clinical advancements. Nat Rev Clin Oncol 2012;9:391-9.
5. Harbour JW, Luo RX, Dei Santi A, Postigo AA, Dean DC. Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1. Cell 1999;98:859-69. (Pubitemid 29446902)
6. Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 2009;9:153-66.
7. Musgrove EA, Caldon CE, Barraclough J, Stone A, Sutherland RL. Cyclin D as a therapeutic target in cancer. Nat Rev Cancer 2011;11:558-72.
8. Anders L, Ke N, Hydbring P, Choi YJ, Widlund HR, Chick JM, et al. A systematic screen for CDK4/6 substrates links FOXM1 phosphorylation to senescence suppression in cancer cells. Cancer Cell 2011;20:620-34.
9. Easton J, Wei T, Lahti JM, Kidd VJ. Disruption of the cyclin D/cyclindependent kinase/INK4/retinoblastoma protein regulatory pathway in human neuroblastoma. Cancer Res 1998;58:2624-32. (Pubitemid 28275436)
10. Krasnoselsky AL, Whiteford CC, Wei JS, Bilke S, Westermann F, Chen QR, et al. Altered expression of cell cycle genes distinguishes aggressive neuroblastoma. Oncogene 2005;24:1533-41. (Pubitemid 40396083)
11. Molenaar JJ, Koster J, Ebus ME, van Sluis P, Westerhout EM, de Preter K, et al. Copy number defects of G1-cell cycle genes in neuroblastoma are frequent and correlate with high expression of E2F target genes and a poor prognosis. Genes Chromosomes Cancer 2012;51:10-9.
12. Molenaar JJ, van Sluis P, Boon K, Versteeg R, Caron HN. Rearrangements and increased expression of cyclin D1 (CCND1) in neuroblastoma. Genes Chromosomes Cancer 2003;36:242-9. (Pubitemid 36158197)
13. Mosse YP, Diskin SJ, Wasserman N, Rinaldi K, Attiyeh EF, Cole K, et al. Neuroblastomas have distinct genomic DNA profiles that predict clinical phenotype and regional gene expression. Genes Chromosomes Cancer 2007;46:936-49. (Pubitemid 47435023)
14. Mosse YP, Greshock J, Margolin A, Naylor T, Cole K, Khazi D, et al. High-resolution detection and mapping of genomic DNA alterations in neuroblastoma. Genes Chromosomes Cancer 2005;43:390-403. (Pubitemid 40946474)
15. Molenaar JJ, Ebus ME, Koster J, van Sluis P, van Noesel CJ, Versteeg R, et al. Cyclin D1 and CDK4 activity contribute to the undifferentiated phenotype in neuroblastoma. Cancer Res 2008;68:2599-609. (Pubitemid 351556258)
16. Cole KA, Huggins J, Laquaglia M, Hulderman CE, Russell MR, Bosse K, et al. RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma. Proc Natl Acad Sci U S A 2011;108:3336-41.
17. Attiyeh EF, Diskin SJ, Attiyeh MA, Mosse YP, Hou C, Jackson EM, et al. Genomic copy number determination in cancer cells from single nucleotide polymorphism microarrays based on quantitative genotyping corrected for aneuploidy. Genome Res 2009;19:276-83.
18. Peddinti R, Zeine R, Luca D, Seshadri R, Chlenski A, Cole K, et al. Prominent microvascular proliferation in clinically aggressive neuroblastoma. Clin Cancer Res 2007;13:3499-506. (Pubitemid 46955109)
19. Russell M, Levin K, Rader J, Belcastro L, Li Y, Martinez D, et al. Combination therapy targeting the Chk1 and Wee1 kinases demonstrates therapeutic efficacy in neuroblastoma. Cancer Res 2013;73:776-84.
20. Bagatell R, London WB, Wagner LM, Voss SD, Stewart CF, Maris JM, et al. Phase II study of irinotecan and temozolomide in children with relapsed or refractory neuroblastoma: a Children's Oncology Group study. J Clin Oncol 2011;29:208-13.
21. Knudsen ES, Wang JY. Differential regulation of retinoblastoma protein function by specific Cdk phosphorylation sites. J Biol Chem 1996;271:8313-20. (Pubitemid 26108665)
22. Connell-Crowley L, Harper JW, Goodrich DW. Cyclin D1/Cdk4 regulates retinoblastoma protein-mediated cell cycle arrest by site-specific phosphorylation. Mol Biol Cell 1997;8:287-301. (Pubitemid 27097944)
23. Kitagawa M, Higashi H, Jung HK, Suzuki-Takahashi I, Ikeda M, Tamai K, et al. The consensus motif for phosphorylation by cyclin D1-Cdk4 is different from that for phosphorylation by cyclin A/E-Cdk2. EMBO J 1996;15:7060-9. (Pubitemid 27023276)
24. Burkhart DL, Sage J. Cellular mechanisms of tumour suppression by the retinoblastoma gene. Nat Rev Cancer 2008;8:671-82.
25. Chicas A, Wang X, Zhang C, McCurrach M, Zhao Z, Mert O, et al. Dissecting the unique role of the retinoblastoma tumor suppressor during cellular senescence. Cancer Cell 2010;17:376-87.
26. Harbour JW, Dean DC. Rb function in cell-cycle regulation and apoptosis. Nat Cell Biol 2000;2:E65-7.
27. Ruas M, Gregory F, Jones R, Poolman R, Starborg M, Rowe J, et al. CDK4 and CDK6 delay senescence by kinase-dependent and p16INK4a-independent mechanisms. Mol Cell Biol 2007;27:4273-82. (Pubitemid 46906552)
28. Wierstra I, Alves J. Transcription factor FOXM1c is repressed by RB and activated by cyclin D1/Cdk4. Biol Chem 2006;387:949-62. (Pubitemid 44100242)
29. Wang Z, Park HJ, Carr JR, Chen YJ, Zheng Y, Li J, et al. FoxM1 in tumorigenicity of the neuroblastoma cells and renewal of the neural progenitors. Cancer Res 2011;71:4292-302.
30. Bresler SC, Wood AC, Haglund EA, Courtright J, Belcastro LT, Plegaria JS, et al. Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma. Sci Transl Med 2011;3:108ra14.
31. Mosse YP, Laudenslager M, Longo L, Cole KA, Wood A, Attiyeh EF, et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 2008;455:930-5.
32. Cheung NK, Zhang J, Lu C, Parker M, Bahrami A, Tickoo SK, et al. Association of age at diagnosis and genetic mutations in patients with neuroblastoma. JAMA 2012;307:1062-71.
33. Molenaar JJ, Koster J, Zwijnenburg DA, van Sluis P, Valentijn LJ, van der Ploeg I, et al. Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes. Nature 2012;483:589-93.
34. Pugh TJ, Morozova O, Attiyeh EF, Asgharzadeh S, Wei JS, Auclair D, et al. The genetic landscape of high-risk neuroblastoma. Nat Genet 2013;45:279-84.
35. Sausen M, Leary RJ, Jones S, Wu J, Reynolds CP, Liu X, et al. Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma. Nat Genet 2013;45:12-7.
36. Canavese M, Santo L, Raje N. Cyclin dependent kinases in cancer: potential for therapeutic intervention. Cancer Biol Ther 2012;13:451-7.
37. Dean JL, McClendon AK, Knudsen ES. Modification of the DNA damage response by therapeutic CDK4/6 inhibition. J Biol Chem 2012;287:29075-87.